AxoSim
Exhibition Partner
AxoSim is a biotechnology company that partners with pharmaceutical companies to foster innovation and facilitate breakthroughs in the treatment of the world’s most devastating neurodegenerative diseases. Drug Discovery platforms NerveSim and BrainSim deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. NerveSim offers a validated tissue model to predict drug neurotoxicity and human efficacy at the earliest stages in drug development pipelines.
Theratechnologies
Industry Partner
Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug conjugate (PDC) that targets the sortilin receptor. In 2021, the FDA granted a Fast-Track Designation to TH1902 for please put a space between development and as a single agent for the treatment of patients with sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy.
www.theratech.com
